ALFA Filings
Every announcement, straight from the exchange
Every Tatva Chintan Pharma Chem earnings call announcement on NSE and BSE, newest first, each with its own page.
Time
7 announcements with these filters
Tatva Chintan reported record quarterly revenue of ₹2,173 Mn for Q2 FY27, up 76% YoY, driven by strong SDA demand. EBITDA margins remained flat at 19% due to high solvent costs and freight spikes.
Tatva Chintan reported strong Q1 FY27 results with 43% YoY revenue growth. Strategy focuses on expanding SDA for Euro 7 standards and commercializing new pharma/semiconductor molecules.
Tatva Chintan reported strong Q1FY27 performance with 43% YoY revenue growth to ₹1,671 Mn. Strategy focuses on green chemistry, R&D in continuous flow, and electrolysis for SDAs.
Tatva Chintan reported Q4 FY26 revenue of ₹1,341 million (up 24% YoY) and EBITDA of ₹281 million (up 214% YoY), driven by improved product mix and operating leverage.
Tatva Chintan reported FY26 revenue of ₹5,059 Mn, up 32% YoY. Growth driven by SDA segment expansion and 'green' chemistry adoption.
Tatva Chintan reported a strong FY26 with revenue up 32% to ₹5,059 Mn and PAT surging 636% to ₹421 Mn. Growth driven by SDA and PASC segments.
Tatva Chintan shows signs of a turnaround with 24% YoY revenue growth, though high raw material costs and geopolitical disruptions in the Middle East persist as headwinds.